Clinical Development

Immunome has successfully priced a public offering, raising approximately $400 million to advance its targeted cancer therapy development. The funds will fuel the advancement of its pipeline, including late-stage drug varegacestat, ROR1 ADC IM-1021, and FAP-targeted radiotherapy IM-3050, as well as early-stage ADC programs. This capital injection signifies strong investor confidence in the company’s innovative oncology approach.

Larimar Therapeutics (LRMR) will host a conference call and webcast on September 29, 2025, at 8:00 am EDT to provide updates on its nomlabofusp clinical development program. The presentation will feature data from the ongoing long-term open-label study evaluating nomlabofusp for the treatment of Friedreich’s ataxia (FA). The company aims to demonstrate the drug’s long-term efficacy and safety in FA patients, addressing a significant unmet medical need. A webcast replay will be available on Larimar’s website.